The impact of the US priority review voucher on private-sector investment in global health research and development.
Main Authors: | Andrew S Robertson, Rianna Stefanakis, Don Joseph, Melinda Moree |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | http://europepmc.org/articles/PMC3429395?pdf=render |
Similar Items
-
Analysis of neglected tropical disease drug and vaccine development pipelines to predict issuance of FDA priority review vouchers over the next decade.
by: Rianna Stefanakis, et al.
Published: (2012-01-01) -
Priority Review Vouchers: GAO Report Provides Scant Evidence of Success
by: Robert J. Meyer
Published: (2021-01-01) -
Is the priority review voucher program stimulating new drug development for tropical diseases?
by: Kirk W Kerr, et al.
Published: (2018-08-01) -
Public–private convergence and the special case of voucher-receiving schools
by: Steven R. Loomis, et al.
Published: (2006-10-01) -
Selection of priority sectors for public-private partnerships
by: E S Bylym, et al.
Published: (2012-03-01)